This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
While Trump’s executive order provides substantial power to Elon Musk’s DOGE eff...
The German drugmaker confirmed acquisition talks, but cautioned a deal may not m...
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and ret...
Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his rol...
The drug is cleared to treat complicated intra-abdominal infections, including t...
Shares in the brain drug developer rose by more than 20% Monday on news of the d...
In what one analyst called a “unique situation,” the company stopped dosing pati...
“There is not a single member of AAM who has not raised concerns about the tarif...
Antibody-drug conjugates (ADCs) are revolutionizing oncology, but success requir...
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter...
The pharmaceutical giant named Jeffrey Legos the head of a division it is counti...
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassurin...
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of ...
The pharmaceutical company plans to cut $2 billion in annual expenses by the end...
The biotech is evaluating several cystic fibrosis medicines that could either wo...
The two biotechs, which have lost most of their share value following lucrative ...
The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3...
Elsewhere, cell therapy developer Turnstone Biologics announced a second round o...
CagriSema, which underperformed expectations in its first Phase 3 test, will be ...